Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers.

Cohen JD, Javed AA, Thoburn C, Wong F, Tie J, Gibbs P, Schmidt CM, Yip-Schneider MT, Allen PJ, Schattner M, Brand RE, Singhi AD, Petersen GM, Hong SM, Kim SC, Falconi M, Doglioni C, Weiss MJ, Ahuja N, He J, Makary MA, Maitra A, Hanash SM, Dal Molin M, Wang Y, Li L, Ptak J, Dobbyn L, Schaefer J, Silliman N, Popoli M, Goggins MG, Hruban RH, Wolfgang CL, Klein AP, Tomasetti C, Papadopoulos N, Kinzler KW, Vogelstein B, Lennon AM.

Proc Natl Acad Sci U S A. 2017 Sep 19;114(38):10202-10207. doi: 10.1073/pnas.1704961114. Epub 2017 Sep 5.

2.

KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control.

Le Calvez-Kelm F, Foll M, Wozniak MB, Delhomme TM, Durand G, Chopard P, Pertesi M, Fabianova E, Adamcakova Z, Holcatova I, Foretova L, Janout V, Vallee MP, Rinaldi S, Brennan P, McKay JD, Byrnes GB, Scelo G.

Oncotarget. 2016 Nov 29;7(48):78827-78840. doi: 10.18632/oncotarget.12386.

3.

Detection of KRAS gene mutations in endoscopic ultrasound-guided fine-needle aspiration biopsy for improving pancreatic cancer diagnosis.

Wang X, Gao J, Ren Y, Gu J, Du Y, Chen J, Jin Z, Zhan X, Li Z, Huang H, Lv S, Gong Y.

Am J Gastroenterol. 2011 Dec;106(12):2104-11. doi: 10.1038/ajg.2011.281. Epub 2011 Aug 30.

PMID:
21876563
4.

High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients.

Allenson K, Castillo J, San Lucas FA, Scelo G, Kim DU, Bernard V, Davis G, Kumar T, Katz M, Overman MJ, Foretova L, Fabianova E, Holcatova I, Janout V, Meric-Bernstam F, Gascoyne P, Wistuba I, Varadhachary G, Brennan P, Hanash S, Li D, Maitra A, Alvarez H.

Ann Oncol. 2017 Apr 1;28(4):741-747. doi: 10.1093/annonc/mdx004.

5.

Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer.

Bernard V, Kim DU, San Lucas FA, Castillo J, Allenson K, Mulu FC, Stephens BM, Huang J, Semaan A, Guerrero PA, Kamyabi N, Zhao J, Hurd MW, Koay EJ, Taniguchi CM, Herman JM, Javle M, Wolff R, Katz M, Varadhachary G, Maitra A, Alvarez HA.

Gastroenterology. 2019 Jan;156(1):108-118.e4. doi: 10.1053/j.gastro.2018.09.022. Epub 2018 Sep 19.

6.

Detection of KRAS Mutations in Circulating Tumor DNA by Digital PCR in Early Stages of Pancreatic Cancer.

Brychta N, Krahn T, von Ahsen O.

Clin Chem. 2016 Nov;62(11):1482-1491. Epub 2016 Sep 2.

7.

Clinical Utility of Circulating Tumor DNA for Molecular Assessment and Precision Medicine in Pancreatic Cancer.

Takai E, Totoki Y, Nakamura H, Kato M, Shibata T, Yachida S.

Adv Exp Med Biol. 2016;924:13-17.

PMID:
27753011
8.

Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer.

Earl J, Garcia-Nieto S, Martinez-Avila JC, Montans J, Sanjuanbenito A, Rodríguez-Garrote M, Lisa E, Mendía E, Lobo E, Malats N, Carrato A, Guillen-Ponce C.

BMC Cancer. 2015 Oct 24;15:797. doi: 10.1186/s12885-015-1779-7.

9.

Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma.

Choi MH, Mejlænder-Andersen E, Manueldas S, El Jellas K, Steine SJ, Tjensvoll K, Sætran HA, Knappskog S, Hoem D, Nordgård O, Hovland R, Molven A.

BMC Cancer. 2019 Jan 5;19(1):11. doi: 10.1186/s12885-018-5195-7.

10.

KRAS mutations in pancreatic circulating tumor cells: a pilot study.

Kulemann B, Liss AS, Warshaw AL, Seifert S, Bronsert P, Glatz T, Pitman MB, Hoeppner J.

Tumour Biol. 2016 Jun;37(6):7547-54. doi: 10.1007/s13277-015-4589-2. Epub 2015 Dec 18.

PMID:
26684803
11.

KRAS mutation analysis of washing fluid from endoscopic ultrasound-guided fine needle aspiration improves cytologic diagnosis of pancreatic ductal adenocarcinoma.

Park JK, Lee YJ, Lee JK, Lee KT, Choi YL, Lee KH.

Oncotarget. 2017 Jan 10;8(2):3519-3527. doi: 10.18632/oncotarget.13864.

12.

Detection of mutant KRAS and TP53 DNA in circulating exosomes from healthy individuals and patients with pancreatic cancer.

Yang S, Che SP, Kurywchak P, Tavormina JL, Gansmo LB, Correa de Sampaio P, Tachezy M, Bockhorn M, Gebauer F, Haltom AR, Melo SA, LeBleu VS, Kalluri R.

Cancer Biol Ther. 2017 Mar 4;18(3):158-165. doi: 10.1080/15384047.2017.1281499. Epub 2017 Jan 25.

13.

KRAS mutation testing on all non-malignant diagnosis of pancreatic endoscopic ultrasound-guided fine-needle aspiration biopsies improves diagnostic accuracy.

Trisolini E, Armellini E, Paganotti A, Veggiani C, Bozzola C, Frattini M, Pizio C, Mancuso G, Andorno S, Boldorini R.

Pathology. 2017 Jun;49(4):379-386. doi: 10.1016/j.pathol.2016.12.348. Epub 2017 Apr 24.

PMID:
28450086
14.

Progression of Chronic Pancreatitis to Pancreatic Cancer: Is There a Role of Gene Mutations as a Screening Tool?

Rashid S, Singh N, Gupta S, Rashid S, Nalika N, Sachdev V, Bal CS, Datta Gupta S, Chauhan SS, Saraya A.

Pancreas. 2018 Feb;47(2):227-232. doi: 10.1097/MPA.0000000000000975.

PMID:
29303908
15.

Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival.

Shin SH, Kim SC, Hong SM, Kim YH, Song KB, Park KM, Lee YJ.

Pancreas. 2013 Mar;42(2):216-22. doi: 10.1097/MPA.0b013e31825b6ab0.

PMID:
23344532
16.

A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma.

Hong TS, Ryan DP, Borger DR, Blaszkowsky LS, Yeap BY, Ancukiewicz M, Deshpande V, Shinagare S, Wo JY, Boucher Y, Wadlow RC, Kwak EL, Allen JN, Clark JW, Zhu AX, Ferrone CR, Mamon HJ, Adams J, Winrich B, Grillo T, Jain RK, DeLaney TF, Fernandez-del Castillo C, Duda DG.

Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):830-8. doi: 10.1016/j.ijrobp.2014.03.034. Epub 2014 May 24.

17.

Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer.

Joergensen MT, Brünner N, De Muckadell OB.

Anticancer Res. 2010 Feb;30(2):587-92.

PMID:
20332475
18.

Circulating tumor cells found in patients with localized and advanced pancreatic cancer.

Kulemann B, Pitman MB, Liss AS, Valsangkar N, Fernández-Del Castillo C, Lillemoe KD, Hoeppner J, Mino-Kenudson M, Warshaw AL, Thayer SP.

Pancreas. 2015 May;44(4):547-50. doi: 10.1097/MPA.0000000000000324.

PMID:
25822154
19.

Value of adding GNAS testing to pancreatic cyst fluid KRAS and carcinoembryonic antigen analysis for the diagnosis of intraductal papillary mucinous neoplasms.

Kadayifci A, Atar M, Wang JL, Forcione DG, Casey BW, Pitman MB, Brugge WR.

Dig Endosc. 2017 Jan;29(1):111-117. doi: 10.1111/den.12710. Epub 2016 Oct 4.

PMID:
27514845
20.

Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy.

Yang KS, Im H, Hong S, Pergolini I, Del Castillo AF, Wang R, Clardy S, Huang CH, Pille C, Ferrone S, Yang R, Castro CM, Lee H, Del Castillo CF, Weissleder R.

Sci Transl Med. 2017 May 24;9(391). pii: eaal3226. doi: 10.1126/scitranslmed.aal3226.

Supplemental Content

Support Center